Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
The AQUA Registry Has Been Approved as a Qualified Clinical Data Registry (QCDR) for the 2023 Reporting Period
For the eighth consecutive year, AUA’s AQUA Registry has been approved, by CMS, as a Qualified Clinical Data Registry (QCDR). For the 2023 reporting year, the AQUA Registry will offer a total of 58 quality measures. This includes 7 Non-QPP, 29 QPP and 20 eCQM (electronic clinical quality) measures. The Registry will also offer 2 test measures (AQUA01 and AUA02), which are meant to be used for internal quality improvement purposes. Please note the test measures cannot be used for 2023 MIPS reporting.
Additionally, the CMS-approved measures address conditions such as prostate cancer, benign prostatic hyperplasia (BPH), urinary stones, bladder cancer and urinary incontinence. The QCDR designation is critical to the success of the AQUA Registry’s efforts to support its participants in fulfilling the reporting requirements set forth by CMS.
advertisement
advertisement